Page last updated: 2024-12-05

paraoxon

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9395
CHEMBL ID23838
CHEBI ID27827
SCHEMBL ID26405
MeSH IDM0015899

Synonyms (107)

Synonym
CHEBI:27827 ,
phosphoric acid diethyl 4-nitrophenyl ester
o,o-diethyl-o-p-nitrophenylphosphoric acid, diethyl-p-nitrophenyl phosphate
ai3-16087
soluglacit
phenol, p-nitro-, ester with diethyl phosphate
o,o'diaethyl-p-nitrophenylphosphat [german]
diethyl-p-nitrofenyl ester kyseliny fosforecne [czech]
p-nitrophenyl diethylphosphate
ethyl p-nitrophenyl ethylphosphate
phosphonothioic acid, diethylparanitrophenyl ester
e-600
diaethyl-p-nitrophenylphosphorsaeureester [german]
mintisal
ccris 7780
o,o-dietyl-o-p-nitrofenylfosfat [czech]
nsc 404110
einecs 206-221-0
rcra waste number p041
soluglaucit
rcra waste no. p041
hsdb 6044
brn 1915526
o,o'diaethyl-p-nitrophenylphosphat
e 600
phosphakol
miotisal
paraoxone
mintaco
hc 2072
phenol, ester with diethyl phosphate
fosfakol
chinorto
ethyl paraoxan
ester 25
paroxan
oxyparathion
ent 16,087
phosphacol
o,o-diethyl o-p-nitrophenyl phosphate
nsc404110
miotisal a
mintacol
eticol
ts 219
wln: wnr dopo & o2 & o2
pestox 101
diethylparaoxon
chinorta
phosphoric acid, diethyl p-nitrophenyl ester
o,o-dietyl-o-p-nitrofenylfosfat
diethyl-p-nitrofenyl ester kyseliny fosforecne
phosphachole
o,o-diethyl phosphoric acid o-p-nitrophenyl ester
phosphoric acid, diethyl 4-nitrophenyl ester
diethyl 4-nitrophenyl phosphate
e 600 (pesticide)
diethyl p-nitrophenyl phosphate
ethyl paraoxon
nsc-404110
diethyl paraoxon
p-nitrophenyl diethyl phosphate
o,o-diethyl o-4-nitrophenyl phosphate
311-45-5
o,o-diethyl-o-p-nitrophenylphosphoric acid
C06606
paraoxon ,
paraoxon, analytical standard
NCGC00164276-01
diethyl-p-nitrophenyl phosphate
e600
bdbm50240416
paraoxon-ethyl
CHEMBL23838 ,
diethyl (4-nitrophenyl) phosphate
NCGC00164276-02
tox21_303047
NCGC00256967-01
dtxcid004046
cas-311-45-5
dtxsid6024046 ,
tox21_202424
NCGC00259973-01
unii-q9cx8p80jw
q9cx8p80jw ,
diaethyl-p-nitrophenylphosphorsaeureester
AKOS015888333
paraoxon [hsdb]
paraoxon [mi]
paraoxon [mart.]
paraoxon [who-dd]
SCHEMBL26405
D10529
o,o-diethyl phosphoric acid, o-(p-nitrophenyl) ester
parathion oxon
parathion ethyl oxon
o,o-diethyl o-(4-nitrophenyl) phosphate, technical grade, 90%
paraoxon-ethyl, pestanal(r), analytical standard
paraoxon-ethyl 100 microg/ml in cyclohexane
J-018260
BCP04403
Q416108
DB13495
phosphoric acid diethyl ester 4-nitro-phenyl ester
paraoxon-ethyl 1000 microg/ml in acetonitrile
o,o-diethyl-phosphoric acid-o-p-nitrophenyl ester
EN300-261419

Research Excerpts

Overview

Paraoxon (POX) is an extremely neurotoxic organophosphorous compound (OP) which main toxic mechanism is the irreversible inhibition of cholinesterase. Paraoxonase 1 (PON1) is a widely studied enzyme based on its protective role against poisoning by OP metabolites of specific OP insecticides.

ExcerptReferenceRelevance
"Paraoxon (POX) is an extremely neurotoxic organophosphorous compound (OP) which main toxic mechanism is the irreversible inhibition of cholinesterase. "( Characterization of acute intrastriatal effects of paraoxon on in vivo dopaminergic neurotransmission using microdialysis in freely moving rats.
Alfonso, M; Durán, R; Fajardo, D; Faro, LRF, 2018
)
2.18
"Paraoxonase 1 (PON1) is a widely studied enzyme based on its protective role against poisoning by organophosphate (OP) metabolites of specific OP insecticides and in vascular disease, as well as its use as biomarker of diseases involving oxidative stress, inflammation and liver diseases.This review provides an update about the current knowledge in the field of the analytical procedures that are used for PON1 measurements. "( Serum paraoxonase 1 (PON1) measurement: an update.
Ceron, JJ; Tecles, F; Tvarijonaviciute, A, 2014
)
2.33
"Paraoxon (POX) is an active metabolite of organophosphate (OP) pesticide parathion that has been weaponized and used against civilian populations. "( Development of status epilepticus, sustained calcium elevations and neuronal injury in a rat survival model of lethal paraoxon intoxication.
Blair, RE; Carter, DS; DeLorenzo, RJ; Deshpande, LS; Phillips, KF, 2014
)
2.05
"Paraoxonase 1 (PON1) is an antioxidative enzyme manly associated with high density lipoproteins (HDL) in the peripheral blood. "( Paraoxonase 1 activity in patients with chronic obstructive pulmonary disease.
Čepelak, I; Grubišić, TŽ; Kopčinović, LM; Pancirov, D; Rajković, MG; Rumora, L, 2014
)
3.29
"Paraoxonase 1 (PON1) is an antioxidant enzyme bound to plasma high-density lipoproteins and is also present in the brain."( Paraoxonase 1 activity in different types of multiple sclerosis.
Bartosik-Psujek, H; Beltowski, J; Jamroz-Wisniewska, A; Stelmasiak, Z, 2009
)
3.24
"Paraoxonase-1 (PON1) is an antioxidant enzyme that attenuates the production of the monocyte chemoattractant protein-1 (MCP-1) in vitro. "( Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients.
Alonso-Villaverde, C; Aragonès, G; Beltrán-Debón, R; Camps, J; Joven, J; Marsillach, J; Parra, S; Rull, A, 2010
)
2.06
"Paraoxonase is a potential marker of survival in patients with breast cancer recurrence."( Paraoxonase 1 (PON1) as a marker of short term death in breast cancer recurrence.
Bard, JM; Bobin-Dubigeon, C; Campone, M; Classe, JM; Hervé, M; Jaffré, I; Joalland, MP, 2012
)
3.26
"Paraoxon is a widely used non-neuropathic organophospate responsible for a large number of accidental or suicidal exposures."( In vitro protection of red blood cell acetylcholinesterase by metoclopramide from inhibition by organophosphates (paraoxon and mipafox).
Arafat, K; Camasamudram, V; Hasan, MY; Kosanovic, M; Petroianu, G; Saleh, A,
)
1.06
"Paraoxon is a non-neuropathic organophosphate responsible for a large number of accidental or suicidal exposures."( Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine.
Arafat, K; Hasan, MY; Petroianu, GA; Schmitt, A,
)
1.09
"Paraoxonase 1 (PON 1) is an enzyme that is promiscuous in its ability to hydrolyze various types of substrates. "( Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis.
Parthasarathy, S; Santanam, N, 2007
)
2.08
"Paraoxonase (PON) is a high-density lipoprotein-bound anti-oxidant enzyme that inhibits atherosclerosis and endothelial dysfunction. "( Association of paraoxonase activity and coronary blood flow.
Celik, H; Demirbag, R; Erel, O; Gur, M; Polat, M; Selek, S; Yildiz, A; Yilmaz, R, 2008
)
2.14
"Paraoxonase is an esterase that hydrolyzes organophosphate compounds. "( Decrease of serum paraoxonase activity in chronic renal failure.
Charmes, JP; Dantoine, TF; Debord, J; Lachatre, G; Leroux-Robert, C; Marquet, P; Merle, L, 1998
)
2.08

Effects

Paraoxonase (PON1) has been termed an environmental response enzyme for its function in the detoxification of organophosphate pesticides, nerve agents and pharmaceuticals. It also plays a cardioprotective role in breaking down oxidized LDL. Paraoxon enzyme activity has been reported to decrease in several situations associated with atherosclerosis and oxidative stress.

ExcerptReferenceRelevance
"Paraoxonase (PON1) has been termed an environmental response enzyme for its function in the detoxification of organophosphate pesticides, nerve agents and pharmaceuticals such as glucocorticoids and statins, as well as its cardioprotective role in breaking down oxidized LDL. "( Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status.
Carlson, CS; Furlong, CE; Jampsa, R; Jarvik, GP; Nickerson, DA; Richter, RJ; Rieder, MJ, 2003
)
2.24
"Paraoxon has traditionally been the substrate for measuring organophosphorus hydrolysing activities."( Comparative hydrolysis of O-hexyl O-2,5-dichlorophenyl phosphoramidate and paraoxon in different tissues of vertebrates.
Monroy-Noyola, A; Rojas, P; Sogorb, MA; Vilanova, E, 2007
)
1.29
"Paraoxonase activity has been reported to decrease in several situations associated with atherosclerosis and oxidative stress."( High-dose taurine supplementation increases serum paraoxonase and arylesterase activities in experimental hypothyroidism.
Dirican, M; Sarandöl, E; Taş, S, 2007
)
1.31
"Paraoxonase activity has been shown to be low in patients with myocardial infarction, diabetes mellitus, or familial hypercholesterolemia."( Decrease of serum paraoxonase activity in chronic renal failure.
Charmes, JP; Dantoine, TF; Debord, J; Lachatre, G; Leroux-Robert, C; Marquet, P; Merle, L, 1998
)
1.36

Actions

ExcerptReferenceRelevance
"Paraoxon is known to cause endogenous acetylcholine poisoning."( Control of blood pressure, heart rate and haematocrit during high-dose intravenous paraoxon exposure in mini pigs.
Bergler, W; Petroianu, A; Petroianu, G; Rüfer, R; Toomes, LM,
)
1.08

Treatment

Paraoxon treatment induced high-frequency bursts in GI axons. Treatment with paraoxon at 100 microg/kg, intramuscularly, resulted in a 3- to 4-fold increase in the number of leaky capillaries in young rats.

ExcerptReferenceRelevance
"In Paraoxon-treated mouse omohyoideus preparations only single end-plate potentials were recorded from end-plates where the membrane potential was not sufficiently negative to support muscle action potentials."( Nature of the anticholinesterase-induced repetitive response of rat and mouse striated muscle to single nerve stimuli.
Clark, AL; Hobbiger, F; Terrar, DA, 1984
)
0.78
"In paraoxon treated rats the G4 form was inhibited by approx."( Differential reactivation by HI-6 in vivo of paraoxon-inhibited rat brain acetylcholinesterase molecular forms.
Bajgar, J; Bisso, GM; Michalek, H, 1995
)
1.06
"The paraoxon-treated animals revealed a significantly lower perfusion rate of the kidney, skeletal muscle, skin and spleen in comparison to the unpoisoned control group."( Regional blood flow determinations in the rat during paraoxon-poisoning and treatment with atropine and obidoxime.
Haase, W; Vetterlein, F, 1979
)
0.99
"2. Paraoxon treatment induced high-frequency bursts in GI axons."( Effects of paraoxon on spike initiation and conduction block in the giant interneurons of the American cockroach, Periplaneta americana.
Drewes, CD; Heppner, TJ, 1989
)
1.18
"Treatment with paraoxon at 100 microg/kg, intramuscularly, resulted in a 3- to 4-fold increase in the number of leaky capillaries in young rats (25 to 30 days old) but not in older rats (90 days old)."( Interactive effects of paraoxon and pyridostigmine on blood-brain barrier integrity and cholinergic toxicity.
Bressler, JP; Lal, B; Murthy, R; Pope, C; Shaikh, J; Song, X, 2004
)
0.97
"Treatment with paraoxon (0.25 mg/kg s.c.) caused approx."( Differential reactivation by HI-6 in vivo of paraoxon-inhibited rat brain acetylcholinesterase molecular forms.
Bajgar, J; Bisso, GM; Michalek, H, 1995
)
0.89
"We treated paraoxon-poisoned rats with 4 x 10 or 4 x 50 mg/kg of quinidine and assessed the severity of the necrotizing myopathy in gastrocnemius and diaphragm muscle biopsies."( Quinidine prevents paraoxon-induced necrotizing myopathy in rats.
De Bleecker, JL; Meire, VI; Pappens, S, 1998
)
1

Toxicity

Methyl parathion (O,O-dimethyl O-P-nitrophenyl phosphorothioate) was used as a pesticide. The toxic metabolite methyl paraoxon was found in the effluent perfusate. Parathion was much less toxic in vitro than in vivo. For TCP and TPP the estimated IC50 values from proliferation assays were lower.

ExcerptReferenceRelevance
" The in vivo protection provided by endogenous CaE was measured by the difference in the LD50 values of OP compounds in control rats and rats whose CaE activity had been inhibited by sc injection with 2 mg/kg of 2-(O-cresyl)-4H-1,3,2-benzodioxaphosphorin-2-oxide."( The specificity of carboxylesterase protection against the toxicity of organophosphorus compounds.
Maxwell, DM, 1992
)
0.28
"Mouse livers perfused in situ with the pesticide methyl parathion (O,O-dimethyl O-P-nitrophenyl phosphorothioate) resulted in the appearance of the toxic metabolite, methyl paraoxon (O,O-dimethyl-O-P-nitrophenyl phosphate), in the effluent perfusate."( The role of the liver in mediating the acute toxicity of the pesticide methyl parathion in the mouse.
Sultatos, LG,
)
0.32
" Twenty minutes later 2 X LD50 of paraoxon was injected sc and the incidence of seizures and death were recorded for 24 hr."( Comparative effects of diazepam and midazolam on paraoxon toxicity in rats.
Domino, EF; Krutak-Krol, H, 1985
)
0.8
" Doses of PO and VX were at or above LD50 levels."( Toxicity of repeated doses of organophosphorus esters in the chicken.
Dacre, JC; Goldman, M; Henderson, JD; Higgins, RJ; Kellner, TP; Wilson, BW, 1988
)
0.27
" The results indicated that mayfly larvae were very sensitive to the toxic effects of acephate, whereas larvae of the stonefly, damselfly and mosquito were much less sensitive."( Studies on the toxicity, metabolism, and anticholinesterase properties of acephate and methamidophos.
Hussain, MA; Mohamad, RB; Oloffs, PC, 1985
)
0.27
" For TCP and TPP the estimated IC50 values from proliferation assays were lower than published LD50 values in vivo, whereas paraoxon was much less toxic in vitro than in vivo."( The toxicity of organophosphate compounds towards cultured PC12 cells.
Flaskos, J; Hargreaves, AJ; McLean, WG, 1994
)
0.5
"Comparison of published LD50 or LC50 levels for a variety of insecticides in several vertebrate species indicate that a wide range of toxicity levels exist, and these cannot be easily predicted within either a chemical group or within a species."( Biochemical mechanisms contributing to species differences in insecticidal toxicity.
Carr, RL; Chambers, JE, 1995
)
0.29
" The animals tolerated an accumulated 6-fold LD50 dose and survived an LD90 dose of carbachol, indicating tolerance to this cholinergic agonist."( Different role of carboxylesterases in toxicity and tolerance to paraoxon and DFP.
Dettbarn, WD; Milatovic, D; Yang, ZP, 1999
)
0.54
" In the present study we evaluated the toxic effect of different concentrations of paraoxon (POX) and parathion (PAT) in murine EL4 T lymphocytes."( Influence of paraoxon (POX) and parathion (PAT) on apoptosis: a possible mechanism for toxicity in low-dose exposure.
Fernandez-Cabezudo, M; Petroianu, G; Saleh, AM; Taleb, M; Vijayasarathy, C,
)
0.73
" To address the question of the difference in toxicity between parathion and chlorpyrifos, the toxic effects of their leaving groups, p-nitrophenol and trichloropyridinol, were studied in mixed-cell aggregates."( Involvement of glial cells in the neurotoxicity of parathion and chlorpyrifos.
Costa, LG; Honegger, P; Monnet-Tschudi, F; Schilter, B; Zurich, MG, 2004
)
0.32
" However, the individual toxic dynamics of diversified OPCs should not be overlooked and further studies with different OPCs are suggested."( Efficacy of N-Acetylcysteine, Glutathione, and Ascorbic Acid in Acute Toxicity of Paraoxon to Wistar Rats: Survival Study.
Adem, A; Kalasz, H; Nurulain, SM; Ojha, S; Shafiullah, M; Tekes, K, 2015
)
0.64
" Using the model of Xenopus laevis embryos, we test the hypothesis that combined exposure of amphibians to natural toxins and anthropogenic pollutants induces more pronounced adverse effects than single exposures."( Mixture toxicity of microcystin-LR, paraoxon and bromadiolone in Xenopus laevis embryos.
Bandouchova, H; Hilscherova, K; Kovacova, V; Linhart, P; Miksikova, M; Mlcakova, V; Ondracek, K; Osickova, J; Pikula, J; Pohanka, M; Skochova, H, 2015
)
0.69
"This study helps to understand adverse effects of environmental pollution by natural toxins and agrochemicals in amphibians."( Mixture toxicity of microcystin-LR, paraoxon and bromadiolone in Xenopus laevis embryos.
Bandouchova, H; Hilscherova, K; Kovacova, V; Linhart, P; Miksikova, M; Mlcakova, V; Ondracek, K; Osickova, J; Pikula, J; Pohanka, M; Skochova, H, 2015
)
0.69
" Although these compounds are extremely toxic agents, the search for novel antidotes remains extremely limited."( Modeling and simulation of organophosphate-induced neurotoxicity: Prediction and validation by experimental studies.
Ambert, N; Barbier, L; Baudry, M; Bischoff, S; Bouteiller, JM; Dadak, S; Dorandeu, F; Fagni, L; Greget, R; Lauga, F; Legendre, A; Linossier-Pierre, S; Moussaoui, S; Pernot, F, 2016
)
0.43
"Safety study of oximes showed no adverse effects on ventilation in rats."( Safety and Efficacy of New Oximes to Reverse Low Dose Diethyl-Paraoxon-Induced Ventilatory Effects in Rats.
Baud, FJ; Houzé, P; Kayouka, M; Kuca, K; Lejay, M, 2020
)
0.8

Pharmacokinetics

ExcerptReferenceRelevance
" These DFP-specific parameter values were used with the model to simulate pharmacokinetic data from mice and rats."( Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters.
Andersen, ME; Clewell, HJ; Conolly, RB; Gearhart, JM; Jepson, GW, 1994
)
0.29
" Pharmacokinetic studies showed that methyl parathion disappeared monoexponentially from plasma and tissues."( Placental transfer and pharmacokinetics of a single dermal dose of [14C]methyl parathion in rats.
Abdel-Rahman, AA; Abou-Donia, MB; Abu-Qare, AW; Kishk, AM, 2000
)
0.31
" However, the pharmacokinetic parameters of parathion were not significantly different after pretreatment with other enzyme inducers compared with respective control rats."( Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats.
Hurh, E; Kim, S; Kim, Y; Lee, A; Lee, E; Lee, M, 2000
)
0.31
"The pharmacokinetic features and metabolism of the novel cytotoxic nucleoside analog Compound 003 (3'-azidothymidine 5'-[p-methoxyphenyl methoxyalaninyl phosphate], CAS 149560-32-7) were studied in both human cancer cells and mice."( In vitro and in vivo pharmacokinetic features and metabolism of the novel cytotoxic nucleoside analog 3'-azidothymidine 5'-[p-methoxyphenyl methoxyalaninyl phosphate] (Compound 003).
Chen, CL; Dibirdik, I; Liu, XP; Uckun, FM; Venkatachalam, TK, 2004
)
0.32
"To develop an HPLC-UV method for determination of a novel antitrypanosomal compound (OSU-36) and its ester prodrug (OSU-40) in rat plasma and to apply the method for pharmacokinetic evaluation of both compounds in rats."( Simultaneous determination of a novel antitrypanosomal compound (OSU-36) and its ester derivative (OSU-40) in plasma by HPLC: application to first pharmacokinetic study in rats.
Gershkovich, P; Lysakowski, S; Premalatha, K; Reid, C; Sivak, O; Wasan, KM; Werbovetz, KA, 2011
)
0.37
" The developed method has been applied for a pharmacokinetic study in rats which revealed that an ester prodrug OSU-40 is rapidly converted to OSU-36 within the plasma compartment by plasma esterases."( Simultaneous determination of a novel antitrypanosomal compound (OSU-36) and its ester derivative (OSU-40) in plasma by HPLC: application to first pharmacokinetic study in rats.
Gershkovich, P; Lysakowski, S; Premalatha, K; Reid, C; Sivak, O; Wasan, KM; Werbovetz, KA, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" After oral administration, peak plasma concentrations were obtained within 3-16 min, and the bioavailability varied from 5 to 71%."( Toxicokinetics of methyl paraoxon in the dog.
Belpaire, F; De Reu, L; De Schryver, E; Willems, J, 1987
)
0.58
" Attachment of a sugar group to the oxime derivative seems to increase the bioavailability of the antidote."( Sugar conjugates of pyridinium aldoximes as antidotes against organophosphate poisoning.
Ashani, Y; Heldman, E; Rachaman, ES; Raveh, L, 1986
)
0.27
"From the presented data, it seems that the concept of uncharged reactivators will have to be modified, at least to improve the bioavailability and to satisfy requirements for in vivo administration."( In vitro and in silico Evaluation of Non-Quaternary Reactivators of AChE as Antidotes of Organophosphorus Poisoning - a New Hope or a Blind Alley?
Box, K; Ceckova, M; Dolezal, R; Gorecki, L; Hepnarova, V; Hrabinova, M; Jankockova, J; Jost, P; Jun, D; Kobrlova, T; Korabecny, J; Kuca, K; Malinak, D; Musilek, K; Nepovimova, E; Nguyen, TD; Outhwaite, B; Pavek, P; Pham, NL; Psotka, M; Sorf, A; Soukup, O, 2018
)
0.48
" The comparison of the results between the intact cells and the lysed cells suggests that the plasma membrane could act as a barrier that reduced the bioavailability of mipafox to PVases."( Hydrolyzing activities of phenyl valerate sensitive to organophosphorus compounds paraoxon and mipafox in human neuroblastoma SH-SY5Y cells.
Del Río, E; Estévez, J; González-González, M; Sogorb, MA; Vilanova, E, 2018
)
0.71

Dosage Studied

Cats were given systemically the anticholinesterase paraoxon at a dosage (3 mg/kg i.075 microg/mL) showed that ethyl paraoxan causes a greater DNA migration that followed a dose-response pattern. A greater intensity was observed in lymphocytes from newborns.

ExcerptRelevanceReference
"The assay of neurotoxic esterase (NTE) in brains taken from dosed hens enables potential neurotoxicity of organophosphate pesticides, plasticers, etc."( Improved assay of neurotoxic esterase for screening organophosphates for delayed neurotoxicity potential.
Johnson, MK, 1977
)
0.26
" The amount of parathion passing through cigarettes as a potential for inhalation exposure ranged up to 28% of dosing levels."( Potential exposure from smoking parathion-contaminated cigarettes.
Comer, SW; Robbins, AL; Staiff, DC, 1977
)
0.26
"17 mg/kg) or moderate dosage (0."( Paraoxon toxicity is not potentiated by prior reduction in blood acetylcholinesterase.
Brimijoin, WS; Moser, VC; Padilla, S; Pope, CN, 1992
)
1.73
"The induction of central-peripheral distal axonopathy in hens singly dosed with some organophosphorus (OP) compounds, such as di-n-butyl-2,2-dichlorovinyl phosphate (DBDCVP), requires greater than 80% organophosphorylation and subsequent intramolecular rearrangement ("aging") of a protein [neuropathy target esterase (NTE)] in the axon."( Progressive deficit of retrograde axonal transport is associated with the pathogenesis of di-n-butyl dichlorvos axonopathy.
Lotti, M; Moretto, A; Sabri, MI; Spencer, PS, 1987
)
0.27
" Light microscopic evaluation revealed a dose-response relationship between the concentration of FEN (10(-2) M to 10(-5) M) and severity of morphologic changes."( Toxic effects of organophosphates on nerve cell growth and ultrastructure in culture.
Bowen, JM; Tuler, SM, 1989
)
0.28
" However, a gene dose-response relationship was observed in the same animals for cytosolic acetyl coenzyme A-dependent 2-aminofluorene N-acetyltransferase activity."( The role of acetylator genotype on hepatic and extrahepatic acetylation, deacetylation, and sulfation of 2-aminofluorene, 2-acetylaminofluorene, and N-hydroxy-2-acetylaminofluorene in the inbred hamster.
Ferguson, RJ; Hein, DW; Kirlin, WG; Ogolla, F; Thompson, LK; Trinidad, A,
)
0.13
" Serum testosterone levels also measured 15 days after dosing were not different from those of a control group."( Neurotoxic esterase in rooster testis.
Becker, CE; Lotti, M; Spear, RC; Wei, ET, 1985
)
0.27
" Based on dosage mortality curves obtained with increasing amounts of atrazine, mortalities of 50 percent of the insect populations would have been achieved with 23, 40, 6, and 10 micrograms of atrazine added to the abovementioned dosages of carbofuran, DDT, parathion, and diazinon, respectively."( Synergism of insecticides by herbicides.
Anderegg, BN; Liang, TT; Lichtenstein, EP, 1973
)
0.25
" Also, a steep dose-response curve for the depressor response to paraoxon is found."( Depressor effects, drug concentration and cholinesterase activities in the brain after administration of paraoxon in the cat.
De Neef, JH; Porsius, AJ; Van Rooy, HH, 1983
)
0.72
" Dose-response curves for the depressor response to paraoxon were established."( Central effects of paraoxon on haemodynamics in the cat.
de Neef, JH; Porsius, AJ, 1981
)
0.84
" Collapsed across dosages, optimal correlations of blood ChE activity with brain or muscle activity occurred 7-21 days after dosing (when ChE inhibition was maximal and most stable)."( Studies on the correlation between blood cholinesterase inhibition and 'target tissue' inhibition in pesticide-treated rats.
Bushnell, PJ; Padilla, S; Wilson, VZ, 1994
)
0.29
") administered 18 h prior to dosing with EC decreased the binding of [14C-ethyl]EC to cellular macromolecules."( The effect of pyridine on the in vitro and in vivo metabolism of ethyl carbamate (urethane) by rat and mouse.
Carlson, GP; Page, DA, 1994
)
0.29
" Effects of repeated, subcutaneous DFP dosing on AChE activity in rat plasma and brain were also well simulated except for an apparent decrease in basal AChE activity in the brain which persisted 35 days after the last dose."( Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters.
Andersen, ME; Clewell, HJ; Conolly, RB; Gearhart, JM; Jepson, GW, 1994
)
0.29
" Dose-response curves were generated for the response to intravenous administration of acetylcholine (ACh), phenylephrine (PE), or salbutamol (SAL) (10(-8) to 10(-4) mol/kg)."( Effect of cyclic phenyl saligenin phosphate and paraoxon treatment on vascular response to adrenergic and cholinergic agents in hens.
Ehrich, M; Lee, JC; McCain, WC; Wilcke, J, 1995
)
0.55
" At 7 and 28 days after dosing action potentials and evoked endplate potentials, produced by stimulating the phrenic nerve at 30 Hz, were recorded in diaphragm muscle."( Effects of multiple doses of organophosphates on evoked potentials in mouse diaphragm.
Blain, PG; de Blaquière, GE; Kelly, SS; Williams, FM, 1997
)
0.3
" The thrombelastographic parameters showed several changes in the POX + ALO series as dosage increased."( In vitro paraoxon (E 600) exposure: no activating effect on human blood coagulation.
Bergler, W; Maleck, W; Petroianu, G; Rüfer, R; Toomes, M, 1997
)
0.71
" The BNF treatment did not seem to alter the degree of inhibition of the brain AChE activity following the low dosage of paraoxon (0."( The effect of high and low dosages of paraoxon in beta-naphthoflavone-treated rats.
Chambers, JE; Watson, AM, 1996
)
0.77
" However, if PMSF is dosed after a low non-neuropathic dose of a neuropathic OP, its neurotoxicity is 'promoted', causing severe neuropathy."( Discrimination of carboxylesterases of chicken neural tissue by inhibition with a neuropathic, non-neuropathic organophosphorus compounds and neuropathy promoter.
Barril, J; Céspedes, MV; Escudero, MA; Sogorb, MA; Vicedo, JL; Vilanova, E, 1997
)
0.3
" The ratio of paraoxon concentration to tissue amount used in in vitro assays of this study was equivalent to dosing a rat with toxicologically relevant dosages."( Detoxication of paraoxon by rat liver homogenate and serum carboxylesterases and A-esterases.
Chambers, JE; Tang, J, 1999
)
1.01
" As expected, based on dose-response and time course studies with Swiss-Webster, C57BL/6, and DBA/2 mice, paraoxon treatment reduced locomotor activity in most, but not all BXD strains."( Quantitative trait loci for acute behavioral sensitivity to paraoxon.
Belknap, JK; Quick, E; Risinger, FO,
)
0.59
") was given 60 min after paraoxon dosing and rats were evaluated for cholinergic toxicity just prior to sacrifice 60 min later."( Combined forced running stress and subclinical paraoxon exposure have little effect on pyridostigmine-induced acute toxicity in rats.
Pope, CN; Shaikh, J, 2003
)
0.88
" We evaluated the effects of daily physical (treadmill running) stress or daily exposure to a subclinical dosage of the organophosphate ChE inhibitor paraoxon (PO) on ChE inhibition in blood, diaphragm and selected brain regions in young adult male Sprague-Dawley rats following subacute PYR exposures."( Effects of daily stress or repeated paraoxon exposures on subacute pyridostigmine toxicity in rats.
Chakraborty, D; Karanth, S; Pope, CN; Pruett, S; Shaikh, J, 2003
)
0.79
" In vivo experiment, NAF and acetylcholinesterase (AChE) activity in the cortical synaptosomes in the adult rats dosed with chlorpyrifos were also determined 96 h after OPs treatment."( [Effect of paraoxon and chlorpyrifos on the nicotinic autoreceptor function in rat cortical synaptosomes].
Carey, P; Sun, YJ; Wu, YJ, 2003
)
0.71
" Oral LD1 values were estimated by dose-response studies (CPF = 80 mg/kg; MPS = 4 mg/kg, in peanut oil, 1 ml/kg)."( Interactive toxicity of the organophosphorus insecticides chlorpyrifos and methyl parathion in adult rats.
Karanth, S; Liu, J; Olivier, K; Pope, C, 2004
)
0.32
" From these results, we predicted that young animals would be more sensitive to diazinon, which, in fact, was the case: When postnatal day (PND) 17 or adult rats were given a dosage of 75 mg/kg diazinon, adult brain cholinesterase (ChE) was only inhibited 38%, while the brain ChE in the PND 17 animals showed much more inhibition (75%)."( Further assessment of an in vitro screen that may help identify organophosphorus pesticides that are more acutely toxic to the young.
Moser, VC; Padilla, S; Sung, HJ, 2004
)
0.32
"075 microg/mL, showed that ethyl paraoxon causes a greater DNA migration that followed a dose-response pattern, a greater intensity being observed in lymphocytes from newborns."( In vitro assessment of the genotoxicity of ethyl paraoxon in newborns and adults.
González-Horta, C; Islas-González, K; Levario-Carrillo, M; Reyes-Aragón, E; Sánchez-Ramírez, B, 2005
)
0.86
" The dose-response relationships showed different curve characteristics with a linear increase of enzyme inhibition compared with a sigmoidal curve for the overt effects."( Comparison of cholin- and carboxylesterase enzyme inhibition and visible effects in the zebra fish embryo bioassay under short-term paraoxon-methyl exposure.
Altenburger, R; Küster, E,
)
0.34
" Additionally, these data raise questions regarding the adequacy of estimating risk of low levels of insecticide exposure from direct extrapolation of insecticide dose-response curves since the capacity of individual oxon molecules at low oxon levels could be greater than individual oxon molecules in vivo associated with the dose-response curve."( Concentration-dependent interactions of the organophosphates chlorpyrifos oxon and methyl paraoxon with human recombinant acetylcholinesterase.
Kaushik, R; Rosenfeld, CA; Sultatos, LG, 2007
)
0.56
" In the specific case of paraoxon and methamidophos in whole blood samples, it was found that dose addition gave a reasonably accurate prediction of the combined effects, despite considerable difference in some of their rate constants, and mildly non-parallel dose-response curves."( Toxicodynamic analysis of the combined cholinesterase inhibition by paraoxon and methamidophos in human whole blood.
Bosgra, S; Langenberg, JP; Slob, W; van der Schans, MJ; van Eijkeren, JC, 2009
)
0.89
" Rats received paraoxon in a dosage of 1, 5, or 10 mumol, and immediately thereafter intraperitoneal injections of the respective oxime at a dosage of half the LD(01)."( Efficacy of eight experimental bispyridinium oximes against paraoxon-induced mortality: comparison with the conventional oximes pralidoxime and obidoxime.
Hasan, MY; Kuca, K; Lorke, DE; Musilek, K; Nurulain, SM; Petroianu, GA; Shafiullah, M, 2009
)
0.95
" Thus, the data presented strongly support the administration of appropriately dosed oximes, preferably obidoxime, in paraoxon-poisoned patients to restore paraoxon-impaired muscle force."( Muscle force and acetylcholinesterase activity in mouse hemidiaphragms exposed to paraoxon and treated by oximes in vitro.
Eyer, P; Thiermann, H; Worek, F, 2010
)
0.8
" We have assessed in vivo the mortality-reducing efficacy of a group of known AChE inhibitors, when given in equitoxic dosage before exposure to the OPC paraoxon."( Usefulness of administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon.
Hasan, MY; Kuča, K; Lorke, DE; Nurulain, SM; Petroianu, GA; Shafiullah, M, 2013
)
0.79
" This kind of interaction among esterase inhibitors should be considered to study the potentiation/promotion phenomenon, which is observed when some esterase inhibitors enhance the severity of the OP induced neuropathy if they are dosed after a non neuropathic low dose of a neuropathy inducer."( Interactions of neuropathy inducers and potentiators/promoters with soluble esterases.
Estévez, J; Mangas, I; Sogorb, MÁ; Vilanova, E, 2013
)
0.39
" AChE inhibitors were given intraperitoneally in equitoxic dosage (25% of LD₀₁) 30 min before OPC exposure."( Acetylcholinesterase inhibitors as pretreatment before acute exposure to organophosphates: assessment using methyl-paraoxon.
Hasan, MY; Kuča, K; Lorke, DE; Nurulain, SM; Petroianu, GA; Shafiullah, M, 2012
)
0.59
" The behavioural defects were dose-response related and persistent."( Developmental exposure to the polybrominated diphenyl ether PBDE 209: Neurobehavioural and neuroprotein analysis in adult male and female mice.
Buratovic, S; Eriksson, P; Fredriksson, A; Viberg, H, 2014
)
0.4
" Lethality was increased by AM251 with the higher dosage of PO, but no lethality was noted with either dosage of CPO, with or without AM251."( The cannabinoid receptor antagonist AM251 increases paraoxon and chlorpyrifos oxon toxicity in rats.
Liu, J; Pope, C, 2015
)
0.67
" Out of 10(7) variants of PobR, four were active when dosed with pNP, with two mutants showing a specificity switch from the native effector 4-hydroxybenzoate (4HB)."( A microbial sensor for organophosphate hydrolysis exploiting an engineered specificity switch in a transcription factor.
Jedrzejczak, R; Jha, RK; Joachimiak, A; Kern, TL; Kim, Y; Strauss, CE; Tesar, C, 2016
)
0.43
" Thus, the present study aimed to investigate the time-course and dose-response efficacy of a brief 4min isoflurane administration as a treatment for neurotoxicity induced by OP-CTA."( Brief isoflurane administration as a post-exposure treatment for organophosphate poisoning.
Appu, AP; Arun, P; Braga, MF; Figueiredo, TH; Flagg, T; Krishnan, JKS; Moffett, JR; Namboodiri, AM; Puthillathu, N, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 3.1.1.7 (acetylcholinesterase) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aryl dialkyl phosphateAny aryl phosphate having a single aryl substituent and two alkyl substituents.
organophosphate insecticide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
triacylglycerol degradation78
paraoxon degradation15

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency0.11010.002541.796015,848.9004AID1347395; AID1347397; AID1347398; AID1347399
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency40.08433.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency31.21790.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency55.62740.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency55.62740.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency36.47350.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency39.55740.000221.22318,912.5098AID1259243; AID1259247; AID588515; AID743035; AID743042; AID743054; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency51.91590.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency20.98230.000417.946075.1148AID1346784; AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency54.94100.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency31.01210.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.00180.000817.505159.3239AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency12.22650.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency24.47910.375827.485161.6524AID588526; AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency55.49290.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency37.33530.000229.305416,493.5996AID1259248; AID743069; AID743075; AID743078; AID743080; AID743091
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency24.26420.001019.414170.9645AID588536; AID588537; AID743191
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency28.24300.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency26.19170.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency13.973019.739145.978464.9432AID1159509
heat shock protein beta-1Homo sapiens (human)Potency55.62740.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency28.78440.000627.21521,122.0200AID651741; AID743202; AID743219
Cellular tumor antigen p53Homo sapiens (human)Potency20.34680.002319.595674.0614AID651631; AID651743
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Mus musculus (house mouse)IC50 (µMol)5.90000.00461.07755.9000AID503576
Carbonic anhydrase 1Homo sapiens (human)IC50 (µMol)0.33800.00582.14107.9000AID525930
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)0.05900.00021.10608.3000AID525933
CholinesteraseHomo sapiens (human)IC50 (µMol)0.00700.00001.559910.0000AID1466192
Muscarinic acetylcholine receptor DM1Drosophila melanogaster (fruit fly)Ki100.00000.00051.42495.2000AID1090601; AID1090602
AcetylcholinesteraseMus musculus (house mouse)IC50 (µMol)0.01300.00071.11818.4000AID503579
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)0.01000.00000.933210.0000AID1466197
Carbonic anhydrase 13Mus musculus (house mouse)IC50 (µMol)1.02100.49000.90271.0500AID525936
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseElectrophorus electricus (electric eel)Kd170.00000.01600.80652.2000AID1466196
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (160)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (50)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (56)

Assay IDTitleYearJournalArticle
AID525931Ratio of Kcat to Km for human carbonic anhydrase 22010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of α- but not of β-, γ- and ζ-carbonic anhydrases.
AID1090109Irreversible inhibition of Diabrotica undecimpunctata (Southern corn rootworm) acetylcholinesterase using acetylcholine iodine as substrate at 300 nM measured after 120 min by DTNB-based colorimetric analysis2002Bioorganic & medicinal chemistry, Mar, Volume: 10, Issue:3
Tricyclic cyanoguanidines: synthesis, site of action and insecticidal activity of a novel class of reversible acetylcholinesterase inhibitors.
AID155743Inhibitory activity against human serum paraoxonase (PON1); Not active2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Structure-activity relationship on human serum paraoxonase (PON1) using substrate analogues and inhibitors.
AID1090110Inhibition of Diabrotica undecimpunctata (Southern corn rootworm) acetylcholinesterase using acetylcholine iodine as substrate at 300 nM measured after 30 min by DTNB-based colorimetric analysis2002Bioorganic & medicinal chemistry, Mar, Volume: 10, Issue:3
Tricyclic cyanoguanidines: synthesis, site of action and insecticidal activity of a novel class of reversible acetylcholinesterase inhibitors.
AID459096Inhibition of electric eel recombinant AChE2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Inhibition of acetylcholinesterase by chromophore-linked fluorophosphonates.
AID231140Ratio of kinetic constant Kcat to Km Sp and Kcat to Km Rp from initial velocity assay against OPAA from Alteromonas sp. JD6.5; No data2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Substrate and stereochemical specificity of the organophosphorus acid anhydrolase from Alteromonas sp. JD6.5 toward p-nitrophenyl phosphotriesters.
AID741586Inhibition of human recombinant AChE by concentration-dependent inhibition assay2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Synthesis and anti-acetylcholinesterase properties of novel β- and γ-substituted alkoxy organophosphonates.
AID1090599Displacement of [3H]QNB from Drosophila melanogaster mAChR at 100000 nM by scintillation counting2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID26095pKa rate constant at 25 degree Centigrade1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Sulfur derivatives of 2-oxopropanal oxime as reactivators of organophosphate-inhibited acetylcholinesterase in vitro: synthesis and structure-reactivity relationships.
AID741587Inhibition of electric eel AChE by concentration-dependent inhibition assay2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Synthesis and anti-acetylcholinesterase properties of novel β- and γ-substituted alkoxy organophosphonates.
AID227955Ratio of kinetic constant Kcat to Km by linear fit to data against OPAA from Alteromonas sp. JD6.52000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Substrate and stereochemical specificity of the organophosphorus acid anhydrolase from Alteromonas sp. JD6.5 toward p-nitrophenyl phosphotriesters.
AID503381Displacement of 2-arachidonylglycerol from MAGL in Swiss Webster mouse brain after 5 mins2008Nature chemical biology, Jun, Volume: 4, Issue:6
Activation of the endocannabinoid system by organophosphorus nerve agents.
AID525932Activity at human carbonic anhydrase 2 by UV-vis spectroscopy2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of α- but not of β-, γ- and ζ-carbonic anhydrases.
AID1090112Insecticidal activity against Nephotettix cincticeps (green rice leafhopper) infested in compound-pretreated rice seedling measured 6 days post-infestation2002Bioorganic & medicinal chemistry, Mar, Volume: 10, Issue:3
Tricyclic cyanoguanidines: synthesis, site of action and insecticidal activity of a novel class of reversible acetylcholinesterase inhibitors.
AID525928Ratio of Kcat to Km for human carbonic anhydrase 12010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of α- but not of β-, γ- and ζ-carbonic anhydrases.
AID1466197Inhibition of human AChE using p-nitrophenyl acetate as substrate measured for 30 secs by spectrophotometric analysis
AID1101165Inhibition of AChE in organophosphate-resistant clone of Schizaphis graminum OR2 adult or last-instar nymphs homogenates assessed as bimolecular rate constant pre-incubated with compound for 2 min at 25 degC before addition of ATC and DTNB solution2000Journal of agricultural and food chemistry, Oct, Volume: 48, Issue:10
Comparative toxicity of selected organophosphate insecticides against resistant and susceptible clones of the greenbug, Schizaphis graminum (Homoptera: aphididae).
AID503579Displacement of acetylcholine from AChE in Swiss Webster mouse brain after 5 mins2008Nature chemical biology, Jun, Volume: 4, Issue:6
Activation of the endocannabinoid system by organophosphorus nerve agents.
AID503576Displacement of [3H]anandamide from FAAH in Swiss Webster mouse brain after 5 mins2008Nature chemical biology, Jun, Volume: 4, Issue:6
Activation of the endocannabinoid system by organophosphorus nerve agents.
AID409760Displacement of [3H]CP-55940 from CB1 receptor in mouse brain2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels.
AID460996Inhibition of electric eel AChE at 10 uM by Ellman's assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Bisquaternary pyridinium oximes: Comparison of in vitro reactivation potency of compounds bearing aliphatic linkers and heteroaromatic linkers for paraoxon-inhibited electric eel and recombinant human acetylcholinesterase.
AID150557Kinetic constant Km from initial velocity assay against Organophosphorus acid anhydrolase from Alteromonas sp. JD6.52000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Substrate and stereochemical specificity of the organophosphorus acid anhydrolase from Alteromonas sp. JD6.5 toward p-nitrophenyl phosphotriesters.
AID741583Inhibition of rat brain AChE by time-dependent inhibition assay2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Synthesis and anti-acetylcholinesterase properties of novel β- and γ-substituted alkoxy organophosphonates.
AID1101166Inhibition of AChE in organophosphate-resistant clone of Schizaphis graminum OR1 adult or last-instar nymphs homogenates assessed as bimolecular rate constant pre-incubated with compound for 2 min at 25 degC before addition of ATC and DTNB solution2000Journal of agricultural and food chemistry, Oct, Volume: 48, Issue:10
Comparative toxicity of selected organophosphate insecticides against resistant and susceptible clones of the greenbug, Schizaphis graminum (Homoptera: aphididae).
AID150555Kinetic constant Kcat from initial velocity assay (at 7.6 mM substrate) against Organophosphorus acid anhydrolase from Alteromonas sp. JD6.52000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Substrate and stereochemical specificity of the organophosphorus acid anhydrolase from Alteromonas sp. JD6.5 toward p-nitrophenyl phosphotriesters.
AID1880635Tanol-water partition coefficient, logP of compound by shake flask method based 31P-NMR analysis2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Studying Lipophilicity Trends of Phosphorus Compounds by
AID1090113Insecticidal activity against Nilaparvata lugens (brown planthopper) infested in compound-pretreated rice seedling measured 6 days post-infestation2002Bioorganic & medicinal chemistry, Mar, Volume: 10, Issue:3
Tricyclic cyanoguanidines: synthesis, site of action and insecticidal activity of a novel class of reversible acetylcholinesterase inhibitors.
AID231138Ratio of kinetic constant K1 to K2 from progress curves against OPAA from Alteromonas sp. JD6.5; No data2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Substrate and stereochemical specificity of the organophosphorus acid anhydrolase from Alteromonas sp. JD6.5 toward p-nitrophenyl phosphotriesters.
AID525934Ratio of Kcat to Km for mouse carbonic anhydrase 132010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of α- but not of β-, γ- and ζ-carbonic anhydrases.
AID1101167Inhibition of AChE in organophosphate-susceptible clone of Schizaphis graminum OSS adult or last-instar nymphs homogenates assessed as bimolecular rate constant pre-incubated with compound for 2 min at 25 degC before addition of ATC and DTNB solution2000Journal of agricultural and food chemistry, Oct, Volume: 48, Issue:10
Comparative toxicity of selected organophosphate insecticides against resistant and susceptible clones of the greenbug, Schizaphis graminum (Homoptera: aphididae).
AID525929Activity at human carbonic anhydrase 1 by UV-vis spectroscopy2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of α- but not of β-, γ- and ζ-carbonic anhydrases.
AID525933Inhibition of esterase activity of human carbonic anhydrase 2 by CO2 hydration method2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of α- but not of β-, γ- and ζ-carbonic anhydrases.
AID741584Inhibition of rat brain AChE by concentration-dependent inhibition assay2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Synthesis and anti-acetylcholinesterase properties of novel β- and γ-substituted alkoxy organophosphonates.
AID460998Inhibition of human recombinant AChE at 100 uM by Ellman's assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Bisquaternary pyridinium oximes: Comparison of in vitro reactivation potency of compounds bearing aliphatic linkers and heteroaromatic linkers for paraoxon-inhibited electric eel and recombinant human acetylcholinesterase.
AID8206Time taken for 50% to be consumed by serum PON1 was determined2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Structure-activity relationship on human serum paraoxonase (PON1) using substrate analogues and inhibitors.
AID1101164Resistance index, ratio of bimolecular rate constant Ki for AChE in rganophosphate-resistant clone of Schizaphis graminum OR1 to bimolecular rate constant Ki for AChE in organophosphate-susceptible clone of Schizaphis graminum OSS2000Journal of agricultural and food chemistry, Oct, Volume: 48, Issue:10
Comparative toxicity of selected organophosphate insecticides against resistant and susceptible clones of the greenbug, Schizaphis graminum (Homoptera: aphididae).
AID460999Inhibition of human recombinant AChE at 10 uM by Ellman's assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Bisquaternary pyridinium oximes: Comparison of in vitro reactivation potency of compounds bearing aliphatic linkers and heteroaromatic linkers for paraoxon-inhibited electric eel and recombinant human acetylcholinesterase.
AID525935Activity at mouse carbonic anhydrase 13 by UV-vis spectroscopy2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of α- but not of β-, γ- and ζ-carbonic anhydrases.
AID409757Inhibition of MAGL-mediated 2-arachidonoylglycerol hydrolysis in mouse brain2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels.
AID1466207Inhibition of human AChE assessed as ratio of k2/I
AID460740Inhibition of electric eel AChE at 1 mM by Ellman's assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Bisquaternary pyridinium oximes: Comparison of in vitro reactivation potency of compounds bearing aliphatic linkers and heteroaromatic linkers for paraoxon-inhibited electric eel and recombinant human acetylcholinesterase.
AID1101163Resistance index, ratio of bimolecular rate constant Ki for AChE in rganophosphate-resistant clone of Schizaphis graminum OR2 to bimolecular rate constant Ki for AChE in organophosphate-susceptible clone of Schizaphis graminum OSS2000Journal of agricultural and food chemistry, Oct, Volume: 48, Issue:10
Comparative toxicity of selected organophosphate insecticides against resistant and susceptible clones of the greenbug, Schizaphis graminum (Homoptera: aphididae).
AID525936Inhibition of esterase activity of mouse carbonic anhydrase 13 by CO2 hydration method2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of α- but not of β-, γ- and ζ-carbonic anhydrases.
AID23272Partition coefficient (logP)1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Phosphorus analogues of gamma-aminobutyric acid, a new class of anticonvulsants.
AID409759Inhibition of FAAH-mediated [3H]anandamide hydrolysis in mouse brain2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels.
AID460995Inhibition of electric eel AChE at 100 uM by Ellman's assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Bisquaternary pyridinium oximes: Comparison of in vitro reactivation potency of compounds bearing aliphatic linkers and heteroaromatic linkers for paraoxon-inhibited electric eel and recombinant human acetylcholinesterase.
AID459095Inhibition of mouse recombinant AChE2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Inhibition of acetylcholinesterase by chromophore-linked fluorophosphonates.
AID1466192Inhibition of human BChE using butyrylthiocholine as substrate measured for 30 secs by Ellman's method
AID184635LD50 expresses the acute toxicity measured after 24 hr in rats1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Sulfur derivatives of 2-oxopropanal oxime as reactivators of organophosphate-inhibited acetylcholinesterase in vitro: synthesis and structure-reactivity relationships.
AID1090600Displacement of [3H]AF-DX 384 from Drosophila melanogaster mAChR at 100000 nM by scintillation counting2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID1466196Binding affinity to Electric eel AChE using acetylthiocholine as substrate measured for 30 secs by Ellman's method
AID460997Inhibition of human recombinant AChE at 1 mM by Ellman's assay2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Bisquaternary pyridinium oximes: Comparison of in vitro reactivation potency of compounds bearing aliphatic linkers and heteroaromatic linkers for paraoxon-inhibited electric eel and recombinant human acetylcholinesterase.
AID1090601Displacement of [3H]QNB from Drosophila melanogaster mAChR by scintillation counting2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID525930Inhibition of esterase activity of human carbonic anhydrase 1 by CO2 hydration method2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of α- but not of β-, γ- and ζ-carbonic anhydrases.
AID1090105Irreversible inhibition of Diabrotica undecimpunctata (Southern corn rootworm) acetylcholinesterase using acetylcholine iodine as substrate assessed as activity remaining at 1 uM incubated for 30 min prior to substrate addition by size exclusion chromatro2002Bioorganic & medicinal chemistry, Mar, Volume: 10, Issue:3
Tricyclic cyanoguanidines: synthesis, site of action and insecticidal activity of a novel class of reversible acetylcholinesterase inhibitors.
AID1090602Displacement of [3H]AF-DX 384 from Drosophila melanogaster mAChR by scintillation counting2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,402)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990471 (33.59)18.7374
1990's234 (16.69)18.2507
2000's300 (21.40)29.6817
2010's326 (23.25)24.3611
2020's71 (5.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.67 (24.57)
Research Supply Index7.33 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index66.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.20%)5.53%
Reviews11 (0.73%)6.00%
Case Studies3 (0.20%)4.05%
Observational0 (0.00%)0.25%
Other1,499 (98.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]